Stanford launches study to better understand rare blistering skin disease
NCT ID NCT01019148
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is screening people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic disease that causes painful blisters and open wounds from minor skin contact. Researchers at Stanford want to learn more about the disease and the patients' cells to develop new treatment strategies. The goal is to identify who might be eligible for future treatment studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPIDERMOLYSIS BULLOSA DYSTROPHICA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University School of Medicine
RECRUITINGStanford, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene therapy for 'Butterfly Skin' disease tracked for 15 years in major safety registry
- Anti-Inflammatory drug may ease swallowing in rare skin disease
- Turmeric and blue light may heal blisters in rare skin disease
- New hope for blistering skin diseases: drug targets antibodies to heal wounds
- Gene therapy gel aims to stop skin cancer from coming back in RDEB patients
- New cream could help kids with 'Butterfly Skin' heal faster